Download You can the brief scientific profile of invited speakers.

THE INVITED SPEAKERS – BRIEF SCIENTIFIC PROFILE
“Cancer2006: From molecular biology processes to tumor-tailored therapy”
20-24, august, 2006 High Tatras, Slovakia
KEYNOTE LECTURE No.1
Andy Futreal, PhD.
Co-head of the Cancer Genome Project
Wellcome Trust Sanger Institute
Hinxton, United Kingdom
Title of the lecture:
The WTSI Cancer genome Project: understanding the targets
PUBLICATIONS:
•
Wooster R, Futreal AP, Stratton MR. Sequencing Analysis of BRAF
Mutations in Human Cancers. Methods Enzymol. 2005
•
Futreal PA, Wooster R, Stratton MR. Somatic mutations in human cancer:
insights from resequencing the protein kinase gene family. Cold Spring
Harb Symp Quant Biol. 2005
•
Stratton MR, Wooster RW, Futreal PA. The BRAF gene is frequently
mutated in malignant melanoma. J Drugs Dermatol. 2004
•
Blow M, Futreal PA, Wooster R, Stratton MR. A survey of RNA editing in
human brain. Genome Res. 2004
•
Stratton MR, Futreal PA. Cancer: understanding the target. Nature. 2004
•
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman
N, Stratton MR. A census of human cancer genes. Nat Rev Cancer. 2004
KEYNOTE LECTURE No. 2
Prof. Josef Jiricny
Director, Institute of Molecular Cancer Research
University of Zürich, Switzerland
Title of the lecture:
Towards the therapy of tumors
with microsatellite instability
PUBLICATIONS:
• Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol
2006
• Cejka P, Stojic L, Marra G, Jiricny J. Is mismatch repair really required for
ionizing radiation-induced DNA damage signaling? Nat Genet 2004
• Jiricny J. An APE that proofreads. Nature 2002
• Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, D'Arrigo A, Truong
O, Hsuan JJ, Jiricny J. GTBP, a 160-kilodalton protein essential for
mismatch-binding activity in human cells. Science 1995
• Brown TC, Jiricny J. Different base/base mispairs are corrected with
different efficiencies and specificities in monkey kidney cells. Cell. 1988
KEYNOTE LECTURE No. 3
Ivan Horak, MD.
Vice - Director Enzon Pharmaceuticals, Inc.
Research and Development
New Jersey, USA
Title of the lecture:
Targeted therapy: from bench to
bedside
PUBLICATIONS:
•
Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ,
Ragland DR, Horak ID, Goldenberg DM. Therapeutic advantage of
pretargeted radioimmunotherapy using a recombinant bispecific antibody in
a human colon cancer xenograft. Clin Cancer Res. 2005
•
Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ,
Hansen HJ, Horak ID, Goldenberg DM. Signal amplification in molecular
imaging by pretargeting a multivalent, bispecific antibody. Nat Med. 2005
•
Govindan SV, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM. Cancer
therapy with radiolabeled and drug/toxin-conjugated antibodies. Technol
Cancer Res Treat. 2005
•
Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA,
Pfreundschuh M, Waldmann TA, Horak ID. Effects of the tyrosine-kinase
inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor
expression and proliferation of Her-2-positive malignant cell lines. Int J
Cancer. 1997
•
Horak ID, Popovic M, Horak EM, Lucas PJ, Gress RE, June CH, Bolen JB.
No T-cell tyrosine protein kinase signalling or calcium mobilization after CD4
association with HIV-1 or HIV-1 gp120. Nature. 1990
Session 1: RETROVIRUSES IN MALIGNANT TRANSFORMATION
Prof. Kathleen Boris-Lawrie
Department of Veterinary Sciences
The Ohio State University, USA
Title of the lecture:
New insight into translational
regulation of growth control
genes: lessons derived from
study of retroviruses
PUBLICATIONS:
•
Younis I, Boris-Lawrie K, Green PL. Human T-cell leukemia virus open reading
frame II encodes a posttranscriptional repressor that is recruited at the level of
transcription. J Virol. 2006
•
Altanerova V, Holicova D, Kucerova L, Altaner C, Lairmore MD, Boris-Lawrie K.
Long-term infection with retroviral structural gene vector provides protection
against bovine leukemia virus disease in rabbits. Virology. 2004
•
Roberts TM, Boris-Lawrie K. Primary sequence and secondary structure motifs
in spleen necrosis virus RU5 confer translational utilization of unspliced human
immunodeficiency virus type 1 reporter RNA. J Virol. 2003
•
Butsch M, Boris-Lawrie K. Destiny of unspliced retroviral RNA: ribosome and/or
virion? J Virol. 2002
•
Butsch M, Hull S, Wang Y, Roberts TM, Boris-Lawrie K. The 5' RNA terminus of
spleen necrosis virus contains a novel posttranscriptional control element that
facilitates human immunodeficiency virus Rev/RRE-independent Gag production.
J Virol. 1999
Session 1: RETROVIRUSES IN MALIGNANT TRANSFORMATION
Prof. Richard Kettmann
Faculty of Agronomy, Gembloux, Belgium
Title of the lecture:
Metabolic pathways involved in
transformational induced by
oncoviral Tax proteins
PUBLICATIONS:
•
Debacq C, Heraud JM, Asquith B, Bangham C, Merien F, Moules V, Mortreux F,
Wattel E, Burny A, Kettmann R, Kazanji M, Willems L. Reduced cell turnover in
lymphocytic monkeys infected by human T-lymphotropic virus type 1. Oncogene.
2005
•
Twizere JC, Lefebvre L, Collete D, Debacq C, Urbain P, Heremans H, Jauniaux
JC, Burny A, Willems L, Kettmann R. The homeobox protein MSX2 interacts with
tax oncoproteins and represses their transactivation activity. J Biol Chem. 2005
•
Dequiedt F, Van Lint J, Lecomte E, Van Duppen V, Seufferlein T, Vandenheede
JR, Wattiez R, Kettmann R. Phosphorylation of histone deacetylase 7 by protein
kinase D mediates T cell receptor - induced Nur77 expression and apoptosis.
J Exp Med. 2005
•
Poturnajova M, Altanerov V, Kettmann R, Feikova S, Hlubinova K, Balazovjech I,
Breza J, Fodo G, Knotek J, Matoska J, Podobov M, Altaner C. Germline mutation
of the RET proto-oncogene in members of Slovak families with multiple endocrine
neoplasia 2. Neoplasma 2001
Session 1: RETROVIRUSES IN MALIGNANT TRANSFORMATION
Prof. Jan Svoboda
Professor of cellular and molecular biology CU
Institute of Molecular Genetics
Prague, Czech Republic
Title of the lecture:
Cell defense against retroviruses
PUBLICATIONS:
• J. Svoboda: Presence of chicken tumour virus in the sarcoma of the
adult rat inoculated after birth with Rous sarcoma tissue.
Nature 1960
• J. Svoboda: Molecular biology of cell nonpermissiveness to
retroviruses. Has the time come? Gene 1998
• J. Svoboda, J. Geryk, D. Elleder: Heterogeneous pathogenicity of
retroviruses: Lessons from birds, primates, and rodents.
Adv. Canc. Res. 2003
• Hejnar J, Hajkova P, Plachy J, Elleder D, Stepanets V, Svoboda J.
CpG island protects Rous sarcoma virus-derived vectors integrated
into nonpermissive cells from DNA methylation and transcriptional
suppression. Proc Natl Acad Sci U S A. 2001
Session 2: MOLECULAR PATHOGENESIS OF CANCER
Karl Heinimann, PhD.
University of Basel
Switzerland
Title of the lecture:
The mechanism of inactivation of
the wild-type allele in hereditary
cancers such as FAP and HNPCC
PUBLICATIONS:
•
Zhang J, Lindroos A, Ollila S, Russell A, Marra G, Mueller H, Peltomaki P, Plasilova
M, Heinimann K. Gene conversion is a frequent mechanism of inactivation of the
wild-type allele in cancers from MLH1/MSH2 deletion carriers. Cancer Res. 2006
•
Westphalen AA, Russell AM, Buser M, Berthod CR, Hutter P, Plasilova M, Mueller H,
Heinimann K. Evidence for genetic anticipation in hereditary non-polyposis
colorectal cancer. Hum Genet. 2005
•
Crabtree M, Sieber OM, Lipton L, Hodgson SV, Lamlum H, Thomas HJ, Neale K,
Phillips RK, Heinimann K, Tomlinson IP. Refining the relation between 'first hits' and
'second hits' at the APC locus: the 'loose fit' model and evidence for differences in
somatic mutation spectra among patients. Oncogene. 2003
•
Sieber OM, Lamlum H, Crabtree MD, Rowan AJ, Barclay E, Lipton L, Hodgson S,
Thomas HJ, Neale K, Phillips RK, Farrington SM, Dunlop MG, Mueller HJ, Bisgaard
ML, Bulow S, Fidalgo P, Albuquerque C, Scarano MI, Bodmer W, Tomlinson IP,
Heinimann K. Whole-gene APC deletions cause classical familial adenomatous
polyposis, but not attenuated polyposis or "multiple" colorectal adenomas. Proc Natl
Acad Sci U S A. 2002
Session 2: MOLECULAR PATHOGENESIS OF CANCER
Linda Wolff, PhD.
Chief, Leukemogenesis Section
Laboratory of Cellular Oncology, CCR
National Cancer Institute, NIH
Bethesda, USA
Title of the lecture:
Cyclin-dependent kinase
inhibitor p15INK4B in leukemia
and normal hematopoiesis
PUBLICATIONS:
•
Hu X, Bies J, Wolff L. Interferon beta increases c-Myc proteolysis in mouse
monocyte/macrophage leukemia cells. Leuk Res. 2005
•
Schmidt M, Bies J, Tamura T, Ozato K, Wolff L. The interferon regulatory
factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of
tumor suppressor p15(Ink4b) in murine myeloid cells. Blood. 2004
•
Wolff L, Garin MT, Koller R, Bies J, Liao W, Malumbres M, Tessarollo L,
Powell D, Perella C. Hypermethylation of the Ink4b locus in murine myeloid
leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient
mice. Oncogene. 2003
•
Haviernik P, Schmidt M, Hu X, Wolff L. Consistent inactivation of p19(Arf)
but not p15(Ink4b) in murine myeloid cells transformed in vivo by
deregulated c-Myc. Oncogene. 2003
•
Schmidt M, Koller R, Haviernik P, Bies J, Maciag K, Wolff L. Deregulated cMyb expression in murine myeloid leukemias prevents the up-regulation of
p15(INK4b) normally associated with differentiation. Oncogene. 2001
Session 2: MOLECULAR PATHOGENESIS OF CANCER
Juraj Bies, PhD.
National Cancer Institute, NIH
Bethesda, USA
Title of the lecture:
Leukemogenesis and c-Myb: story of a tightly
regulated transcriptional regulator
PUBLICATIONS:
• Markus J, Feikova S, Sramko M, Wolff L, Bies J. Proliferation-linked
expression of the novel murine gene m4mbt encoding a nuclear zinc
finger protein with four mbt domains. Gene. 2003
• Bies J, Markus J, Wolff L. Covalent attachment of the SUMO-1
protein to the negative regulatory domain of the c-Myb transcription
factor modifies its stability and transactivation capacity. J Biol
Chem. 2002
• Bies J, Feikova S, Markus J, Wolff L. Phosphorylation-dependent
conformation and proteolytic stability of c-Myb. Blood Cells Mol
Dis. 2001
• Bies J, Feikova S, Bottaro DP, Wolff L. Hyperphosphorylation and
increased proteolytic breakdown of c-Myb induced by the inhibition
of Ser/Thr protein phosphatases. Oncogene. 2000
• Hu X, Bies J, Wolff L. Interferon beta increases c-Myc proteolysis in
mouse monocyte/macrophage leukemia cells. Leuk Res. 2005
Session 3: DNA DAMAGE AND REPAIR PROCESSES I.
Bennett Van Houten, PhD.
Chief, Program Analysis Branch &
Investigator in the Laboratory of Molecular Genetics
National Institutes of Environmental Health Sciences
Research Triangle Park, NC, USA
Title of the lecture:
In search of damage: Structure-function studies of
nucleotide excision repair
PUBLICATIONS:
•
Santos JH, Meyer JN, Van Houten B. Mitochondrial localization of telomerase as
a determinant for hydrogen peroxide-induced mitochondrial DNA damage and
apoptosis. Hum Mol Genet. 2006
•
Truglio JJ, Karakas E, Rhau B, Wang H, Dellavecchia MJ, Van Houten B, Kisker
C. Structural basis for DNA recognition and processing by UvrB. Nat Struct Mol
Biol. 2006
•
Truglio JJ, Rhau B, Croteau DL, Wang L, Skorvaga M, Karakas E, DellaVecchia
MJ, Wang H, Van Houten B, Kisker C. Structural insights into the first incision
reaction during nucleotide excision repair. EMBO J. 2005
•
Skorvaga M, DellaVecchia MJ, Croteau DL, Theis K, Truglio JJ, Mandavilli BS,
Kisker C, Van Houten B. Identification of residues within UvrB that are important
for efficient DNA binding and damage processing. J Biol Chem. 2004
•
Dubaele S, Proietti De Santis L, Bienstock RJ, Keriel A, Stefanini M, Van Houten
B, Egly JM. Basal transcription defect discriminates between xeroderma
pigmentosum and trichothiodystrophy in XPD patients. Mol Cell. 2003
Session 3: DNA DAMAGE AND REPAIR PROCESSES I.
Prof. Jiri Lukas
Institute of Cancer Biology for
Genotoxic Stress Resarch
Danish Cancer Society, Copenhagen,
Denmark
Title of the lecture:
Cellular response to DNA damage: Molecular mechanism and
spatio-temporal organization in living mammalian cells
PUBLICATIONS:
• Bartek J, Lukas J. Cell biology. The stress of finding NEMO. Science. 2006
• Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P,
Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. DNA
damage response as a candidate anti-cancer barrier in early human
tumorigenesis. Nature. 2005
• Lukas J, Bartek J. Cell division: the heart of the cycle. Nature. 2004
• Lukas J, Bartek J. Watching the DNA repair ensemble dance. Cell. 2004
• Bartek J, Lukas J. Are all cancer genes equal? Nature. 2001
• Bartek J, Lukas J. Cell cycle. Order from destruction. Science. 2001.
Session 3: DNA DAMAGE AND REPAIR PROCESSES I.
Mark O’Driscoll, PhD.
Sussex Centre for Genome Damage and Stability
University of Sussex
Falmer, Brighton
Title of the lecture:
DNA double strands break repair and cancer
predisposition: Lessons from human syndromes
PUBLICATIONS:
•
O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from
human genetics. Nat Rev Genet. 2006
•
Alderton GK, Joenje H, Varon R, Borglum AD, Jeggo PA, O'Driscoll M. Seckel
syndrome exhibits cellular features demonstrating defects in the ATR-signalling
pathway. Hum Mol Genet. 2004
•
O'Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA. An overview of three
new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and
ATR-Seckel syndrome. DNA Repair (Amst). 2004
•
Gennery AR, O'Driscoll M. Unravelling the web of DNA repair disorders. Clin Exp
Immunol. 2003
•
O'Driscoll M, Jeggo PA. Clinical impact of ATR checkpoint signalling failure in
humans. Cell Cycle. 2003
Session 4: DNA DAMAGE AND REPAIR PROCESSES II.
Miroslav Chovanec, PhD.
Senior investigator
Laboratory of Molecular Genetics
Cancer Research Institute of Slovak
Academy of Sciences
Bratislava
Title of the lecture:
Cellular response to oxidative
DNA damage in
Saccharomyces cerevisiae
PUBLICATIONS:
• Dudas A, Markova E, Vlasakova D, Kolman A, Bartosova Z,
Brozmanova J, Chovanec M. The Escherichia coli RecA protein
complements recombination defective phenotype of the
Saccharomyces cerevisiae rad52 mutant cells. Yeast. 2003
• Dudas A, Chovanec M. DNA double-strand break repair by
homologous recombination. Mutat Res. 2004
• Dudasova Z, Dudas A, Chovanec M. Non-homologous end-joining
factors of Saccharomyces cerevisiae. FEMS Microbiol Rev. 2004
• Brozmanova J, Vlckova V, Chovanec M. How heterologously
expressed Escherichia coli genes contribute to understanding DNA
repair processes in Saccharomyces cerevisiae. Curr Genet. 2004
• Kysela B, Chovanec M, Jeggo PA. Phosphorylation of linker
histones by DNA-dependent protein kinase is required for DNA
ligase IV-dependent ligation in the presence of histone H1. Proc
Natl Acad Sci U S A. 2005
Session 4: DNA DAMAGE AND REPAIR PROCESSES II.
Miroslav Pirsel, PhD.
Head of Laboratory of Molecular Genetics
Cancer Research Institute of Slovak
Academy of Sciences
Bratislava
Title of the lecture:
Repair of oxidative DNA
damage in the helicase mutants
PUBLICATIONS:
•
Wassermann K, Pirsel M, Bohr VA. Overexpression of metallothionein in
Chinese hamster ovary cells and its effect on nitrogen mustard - induced
cytotoxicity: role of gene-specific damage and repair. Cancer Res. 1992
•
Pirsel M, Bohr VA. Methyl methanesulfonate adduct formation and repair in
the DHFR gene and in mitochondrial DNA in hamster cells.
Carcinogenesis. 1993
•
Sedliakova M, Slezarikova V, Masek F, Vizvaryova M, Pirsel M. Role of
DNA polymerase II in the tolerance of thymine dimers remaining unexcised
in UV-irradiated Escherichia coli exposed to pre-UV nutritional stress.
J Photochem Photobiol B. 2001
•
Hall H, Gursky J, Nicodemou A, Rybanska I, Kimlickova E, Pirsel M.
Characterization of ERCC3 mutations in the Chinese hamster ovary 27-1,
UV24 and MMC-2 cell lines. Mutat Res. 2006
•
Pirsel M, Chovanec M, Dudas A, Kleibl K, Van Houten B. Fourth DNA
repair workshop on DNA damage and repair: mechanisms and biological
consequences Smolenice Castle, 2-5 May 2004. DNA Repair (Amst). 2004
Session 5: CANCER GENETICS
Minna Nystrom, PhD.
Senior scientist & Research Manager
Department of Biological and Environmental Sciences
University of Helsinki, Finland
Title of the lecture:
Functional significance and clinical
phenotype of non-truncating inherited
mismatch repair gene variants
PUBLICATIONS:
•
Raevaara TE, Korhonen MK, Lohi H, Hampel H, Lynch E, Lonnqvist KE, Holinski-Feder E,
Sutter C, McKinnon W, Duraisamy S, Gerdes AM, Peltomaki P, Kohonen-Ccorish M, Mangold
E, Macrae F, Greenblatt M, de la Chapelle A, Nystrom M. Functional significance and clinical
phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology. 2005
•
Kariola R, Abdel-Rahman WM, Ollikainen M, Butzow R, Peltomaki P, Nystrom M. APC and
beta-catenin protein expression patterns in HNPCC-related endometrial and colorectal cancers.
Fam Cancer. 2005
•
Nystrom-Lahti M, Kristo P, Nicolaides NC, Chang SY, Aaltonen LA, Moisio AL, Jarvinen HJ,
Mecklin JP, Kinzler KW, Vogelstein B, et al. Founding mutations and Alu-mediated
recombination in hereditary colon cancer. Nat Med. 1995
•
Nystrom-Lahti M, Sistonen P, Mecklin JP, Pylkkanen L, Aaltonen LA, Jarvinen H, Weissenbach
J, de la Chapelle A, Peltomaki P. Close linkage to chromosome 3p and conservation of
ancestral founding haplotype in hereditary nonpolyposis colorectal cancer families. Proc Natl
Acad Sci U S A. 1994
•
Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P,
Aaltonen LA, Nystrom-Lahti M, et al. Mutations of a mutS homolog in hereditary
nonpolyposis colorectal cancer. Cell. 1993
Session 5: CANCER GENETICS
Vladimir Zajac, PhD.
Head of Laboratory of Cancer Genetics
Cancer Research Institute of Slovak
Academy of Sciences
Bratislava
Title of the lecture:
FAP and HBOC: two players in
one playground
PUBLICATIONS:
•
Ciernikova S, Tomka M, Kovac M, Stevurkova V, Zajac V. Ashkenazi
founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or
ovarian cancer families. Neoplasma. 2006
•
Kovac M, Tomka M, Ciernikova S, Stevurkova V, Valachova A, Zajac V.
Multiple gynecologic tumors as rare associated phenotypes of FAP/Gardner
syndrome in a family with the novel germline mutation in the APC gene.
Clin Genet. 2006
•
Mego M, Koncekova R, Mikuskova E, Drgona L, Ebringer L, Demitrovicova
L, Nemova I, Trupl J, Mardiak J, Koza I, Zajac V. Prevention of febrile
neutropenia in cancer patients by probiotic strain Enterococcus faecium M74. Phase II study. Support Care Cancer. 2006
•
Anker P, Zajac V, Lyautey J, Lederrey C, Dunand C, Lefort F, Mulcahy H,
Heinemann J, Stroun M. Transcession of DNA from bacteria to human cells
in culture: a possible role in oncogenesis. Ann N Y Acad Sci. 2004
•
Zajac V, Kirchhoff T, Levy ER, Horsley SW, Miller A, Steichen-Gersdorf E,
Monaco AP. Characterisation of X;17(q12;p13) translocation breakpoints in
a female patient with hypomelanosis of Ito and choroid plexus papilloma.
Eur J Hum Genet. 1997
Session 5: CANCER GENETICS
Zdena Bartosova, PhD.
Senior investigator
Laboratory of Molecular Genetics
Cancer Research Institute of Slovak
Academy of Sciences
Bratislava
Title of the lecture:
Advances in molecular diagnostics of hereditary
non-polyposis colorectal cancer in Slovakia
PUBLICATIONS:
•
Venema J, Bartosova Z, Natarajan AT, van Zeeland AA, Mullenders LH.
Transcription affects the rate but not the extent of repair of cyclobutane
pyrimidine dimers in the human adenosine deaminase gene. J Biol Chem.
1992
•
Bartosova Z, Pirsel M, Reinhold W, Stetler-Stevenson M, Zajac-Kaye M,
May A, Horak ID, Bohr VA. Gene-specific repair in human CD4+
lymphocytes reflects transcription and proliferation. Mutat Res. 1996
•
Marra G, D'Atri S, Corti C, Bonmassar L, Cattaruzza MS, Schweizer P,
Heinimann K, Bartosova Z, Nystrom-Lahti M, Jiricny J . Tolerance of
human MSH2+/- lymphoblastoid cells to the methylating agent
temozolomide. Proc Natl Acad Sci U S A. 2001
•
Bartosova Z, Fridrichova I, Bujalkova M, Wolf B, Ilencikova D, Krizan P,
Hlavcak P, Palaj J, Lukac L, Lukacova M, Boor A, Haider R, Jiricny J,
Nystrom-Lahti M, Marra G. Novel MLH1 and MSH2 germline mutations in
the first HNPCC families identified in Slovakia. Hum Mutat. 2003
•
Zavodna K, Bujalkova M, Krivulcik T, Alemayehu A, Skorvaga M, Marra G,
Fridrichova I, Jiricny J, Bartosova Z. Novel and recurrent germline
alterations in the MLH1 and MSH2 genes identified in hereditary
nonpolyposis colorectal cancer patients in Slovakia. Neoplasma 2006
Session 6: TUMOR CELL SIGNALING AND CELL DEATH
Prof. Gerhard Christofori
Institute of Biochemistry and Genetics
University of Basel, Switzerland
Title of the lecture:
Cell adhesion in tumor
invasion and metastasis
PUBLICATIONS:
•
Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor
invasion in the absence of epithelial-mesenchymal transition: Podoplaninmediated remodeling of the actin cytoskeleton. Cancer Cell. 2006
•
Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus
contributions by the tumor microenvironment. Cell Mol Life Sci. 2006
•
Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and IgCAMs in cancer. Nat Rev Cancer. 2004
•
Gannon G, Mandriota SJ, Cui L, Baetens D, Pepper MS, Christofori G.
Overexpression of vascular endothelial growth factor-A165 enhances tumor
angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res.
2002
•
Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumourcell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol. 2001
Session 6: TUMOR CELL SIGNALING AND CELL DEATH
Jozef Bizik, PhD., DsC.
Senior investigator
Laboratory of Molecular Oncology
Cancer Research Institute of Slovak
Academy of Sciences
Bratislava
Title of the lecture:
Nemosis – prospective cell
based cancer therapy
PUBLICATIONS:
•
Kankuri E, Cholujova D, Comajova M, Vaheri A, Bizik J. Induction of
hepatocyte growth factor/scatter factor by fibroblast clustering directly
promotes tumor cell invasiveness. Cancer Res. 2005
•
Bizik J, Kankuri E, Ristimaki A, Taieb A, Vapaatalo H, Lubitz W, Vaheri A.
Cell-cell contacts trigger programmed necrosis and induce cyclooxygenase2 expression.
Cell Death Differ. 2004
•
Eleveld-Trancikova D, Kudela P, Majerciak V, Regendova M, Zelnik V,
Pastorek J, Pastorekova S, Bizik J. Suppression subtractive hybridisation
to isolate differentially expressed genes involved in invasiveness of
melanoma cell line cultured under different conditions. Int J Oncol. 2002
•
Vaheri A, Tapiovaara H, Myohanen H, Bizik J. Alpha 2-macroglobulin in the
regulation of pericellular plasminogen activation of human tumor cells. Ann
N Y Acad Sci. 1994
•
Bizik J, Lizonova A, Grofova M, Matoska J, Dore JF, Bertrand S, Blasko M,
Vaheri A. Clonal variation in the production of tumor-associated alpha 2macroglobulin in a malignant human melanoma and association with growth
stimulation. Cancer Res. 1989
Session 7: CARCINOGENESIS / ANTICARCINOGENESIS I.
Prof. Leonard Mullenders
Department of Toxicogenetics
Leiden University Medical Center
Leiden, The Netherlands
Title of the lecture:
From initial DNA damage to
cancer: Lessons from mouse
models
PUBLICATIONS:
•
Alekseev S, Kool H, Rebel H, Fousteri M, Moser J, Backendorf C, de Gruijl FR,
Vrieling H, Mullenders LH. Enhanced DDB2 expression protects mice from
carcinogenic effects of chronic UV-B irradiation. Cancer Res. 2005
•
Fousteri M, van Hoffen A, Vargova H, Mullenders LH. Repair of DNA lesions in
chromosomal DNA impact of chromatin structure and Cockayne syndrome
proteins. DNA Repair (Amst). 2005
•
Riou L, Eveno E, van Hoffen A, van Zeeland AA, Sarasin A, Mullenders LH.
Differential repair of the two major UV-induced photolesions in trichothiodystrophy
fibroblasts. Cancer Res. 2004
•
Buterin T, Hess MT, Gunz D, Geacintov NE, Mullenders LH, Naegeli H. Trapping
of DNA nucleotide excision repair factors by nonrepairable carcinogen adducts.
Cancer Res. 2002
•
Volker M, Mone MJ, Karmakar P, van Hoffen A, Schul W, Vermeulen W,
Hoeijmakers JH, van Driel R, van Zeeland AA, Mullenders LH. Sequential
assembly of the nucleotide excision repair factors in vivo. Mol Cell. 2001
Session 7: CARCINOGENESIS / ANTICARCINOGENESIS I.
Prof. Andrew Collins
Department of Nutrition, University of Oslo
Blindern, Oslo, Norway
Title of the lecture:
Cancer prevention by fruits and
vegetables; not just a question for
antioxidants
PUBLICATIONS:
•
Dusinska M, Dzupinkova Z, Wsolova L, Harrington V, Collins AR. Possible
involvement of XPA in repair of oxidative DNA damage deduced from
analysis of damage, repair and genotype in a human population study.
Mutagenesis. 2006
•
Maitland NJ, Collins A. A tumour stem cell hypothesis for the origins of
prostate cancer. BJU Int. 2005
•
Collins AR. Antioxidant intervention as a route to cancer prevention. Eur J
Cancer. 2005
•
Gedik CM, Grant G, Morrice PC, Wood SG, Collins AR. Effects of age and
dietary restriction on oxidative DNA damage, antioxidant protection and
DNA repair in rats. Eur J Nutr. 2005
•
Collins AR, Ferguson LR. Nutrition and carcinogenesis. Mutation
Research. 2004
Session 8: CARCINOGENESIS / ANTICARCINOGENESIS II.
Prof. Krzysztof Szyfter
Institute of Human Genetics
Polish Academy of Sciences
Poznan, Poland
Title of the lecture:
Modulation of laryngeal cancer
incidence and progression by
gene polymorphism
PUBLICATIONS:
• Rydzanicz M, Wierzbicka M, Gajecka M, Szyfter W, Szyfter K. The impact of
genetic factors on the incidence of multiple primary tumors (MPT) of the
head and neck. Cancer Lett. 2005
• Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter
K. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms
or their combinations are associated with the increased risk of the laryngeal
squamous cell carcinoma. Mutat Res. 2005
• Kujawski M, Jarmuz M, Rydzanicz M, Szukala K, Wierzbicka M, Grenman R,
Golusinski W, Szyfter K. Frequent chromosome Y loss in primary, second
primary and metastatic squamous cell carcinomas of the head and neck
region. Cancer Lett. 2004
• lasiak J, Jaloszynski P, Trzeciak A, Szyfter K. In vitro studies on the
genotoxicity of the organophosphorus insecticide malathion and its two
analogues. Mutat Res. 1999
Session 9: TUMOR-TAILORED THERAPIES
Geoffrey Margison, PhD
Paterson Institute for Cancer Research
senior investigator
Manchester, United Kingdom
Title of the lecture:
DNA repair based strategies
PUBLICATIONS:
•
Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D,
Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D,
McMurry TB, Margison GP. Lomeguatrib, a potent inhibitor of O6-alkylguanineDNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic
trial and evaluation in combination with temozolomide in patients with
advanced solid tumors. Clin Cancer Res. 2006
•
Margison GP, Heighway J, Pearson S, McGown G, Thorncroft MR, Watson
AJ, Harrison KL, Lewis SJ, Rohde K, Barber PV, O'Donnell P, Povey AC,
Santibanez-Koref MF. Quantitative trait locus analysis reveals two intragenic
sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral
blood mononuclear cells. Carcinogenesis. 2005
•
Barvaux VA, Ranson M, Brown R, McElhinney RS, McMurry TB, Margison GP.
Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer
Ther. 2004
•
Middleton MR, Margison GP. Improvement of chemotherapy efficacy by
inactivation of a DNA-repair pathway. Lancet Oncol. 2003
Session 9: TUMOR-TAILORED THERAPIES
Jan Sedlak, PhD.
Deputy director and Head of Laboratory of
Tumor Immunology of Cancer Research
Institute of Slovak Academy of Sciences
Bratislava
Title of the lecture:
A possible role of dietary
chemopreventive compounds in
tumor therapy
PUBLICATIONS:
•
Bodo J, Jakubikova J, Chalupa I, Bartosova Z, Horakova K, Floch L, Sedlak
J. Apoptotic effect of ethyl-4-isothiocyanatobutanoate is associated with
DNA damage, proteasomal activity and induction of p53 and p21(cip1/waf1).
Apoptosis. 2006
•
Slamenova D, Horvathova E, Robichova S, Hrusovska L, Gabelova A, Kleibl
K, Jakubikova J, Sedlak J. Molecular and cellular influences of butylated
hydroxyanisole on Chinese hamster V79 cells treated with N-methyl-N'nitro-N-nitrosoguanidine: antimutagenicity of butylated hydroxyanisole. Int J
Oncol. 2005
•
Jakubikova J, Sedlak J, Bacon J, Goldson A, Bao Y. Effects of MEK1 and
PI3K inhibitors on allyl-, benzyl- and phenylethyl-isothiocyanate-induced
G2/M arrest and cell death in Caco-2 cells. Environ Mol Mutagen. 2003
•
Jakubikova J, Sedlak J, Bod'o J, Bao Y. Effect of isothiocyanates on
nuclear accumulation of NF-kappaB, Nrf2, and thioredoxin in caco-2 cells. J
Agric Food Chem. 2006
•
Jakubikova J, Bao Y, Sedlak J. Isothiocyanates induce cell cycle arrest,
apoptosis and mitochondrial potential depolarization in HL-60 and
multidrug-resistant cell lines. Anticancer Res. 2005
Session 9: TUMOR-TAILORED THERAPIES
Prof. Martin Brendel
Universidade Estadual de Santa Cruz,
Bahia, Brasil
Title of the lecture:
Tumor regression by antisense
therapy against Plk1 and Bcl-2
PUBLICATIONS:
•
Viau C, Pungartnik C, Schmitt MC, Basso TS, Henriques JA, Brendel M.
Sensitivity to Sn(2+) of the Yeast Saccharomyces cerevisiae Depends on
General Energy Metabolism, Metal Transport, Anti-Oxidative Defences, and
DNA Repair. Biometals. 2006
•
Filho DF, Pungartnik C, Cascardo JC, Brendel M. Broken hyphae of the
basidiomycete Crinipellis perniciosa allow quantitative assay of toxicity.
Curr Microbiol. 2006
•
Bonatto D, Brendel M, Henriques JA. In silico identification and analysis of
new Artemis/Artemis-like sequences from fungal and metazoan species.
Protein J. 2005
•
Pungartnik C, Viau C, Picada J, Caldeira-de-Araujo A, Henriques JA,
Brendel M. Genotoxicity of stannous chloride in yeast and bacteria. Mutat
Res. 2005
•
Brendel M, Bonatto D, Strauss M, Revers LF, Pungartnik C, Saffi J,
Henriques JA. Role of PSO genes in repair of DNA damage of
Saccharomyces cerevisiae. Mutat Res. 2003
Session 10: STEM CELLS AND CANCER STEM CELLS
Cestmir Altaner
Director of Cancer Research Institute of
Slovak Academy of Sciences
Bratislava
Title of the lecture:
Normal and cancer stem cells:
potential implication for cancer
therapy
PUBLICATIONS:
•
Soltysova A, Altanerova V, Altaner C. Cancer stem cells. Neoplasma. 2005
•
Poturnajova M, Altanerova V, Kostalova L, Breza J, Altaner C. Novel
germline mutation in the transmembrane region of RET gene close to
Cys634Ser mutation associated with MEN 2A syndrome. J Mol Med. 2005
•
Altanerova V, Holicova D, Kucerova L, Altaner C, Lairmore MD, BorisLawrie K. Long-term infection with retroviral structural gene vector provides
protection against bovine leukemia virus disease in rabbits. Virology. 2004
•
Boris-Lawrie K, Altanerova V, Altaner C, Kucerova L, Temin HM. In vivo
study of genetically simplified bovine leukemia virus derivatives that lack tax
and rex. J Virol. 1997
•
Hladka M, Altaner C. Suppression of the avian sarcoma virus genome in 8azaquanine-resistant, transformed, hamster cells. J Natl Cancer Inst. 1976
•
Altaner C, Temin HM. Carcinogenesis by RNA sarcoma viruses. XII. A
quantitative study of infection of rat cells in vitro by avian sarcoma viruses.
Virology. 1970